8-K: Biora Therapeutics Announces Positive Topline Results for BT-600 Clinical Trial

Biora Therapeutics reports successful Phase 1 clinical trial results for BT-600, demonstrating targeted drug delivery to the colon using its NaviCap platform.

Summary

• Biora Therapeutics has announced positive topline results from its Phase 1 clinical trial of BT-600, a drug-device combination for ulcerative colitis.
• The trial demonstrated that the NaviCap device successfully delivered tofacitinib directly to the colon.
• Systemic absorption of tofacitinib was first observed at six hours, indicating colonic rather than upper gastrointestinal delivery.
• Maximum drug levels were reached at eight to ten hours, compared to 30 minutes for conventional oral tofacitinib.
• The maximum systemic drug exposure was three to four times lower than with conventional oral tofacitinib, highlighting the platform's ability to limit systemic exposure.
• Biopsies confirmed drug exposure extended to the distal colon, suggesting pan-colonic delivery.
• Post-retrieval device analysis showed 100% of devices in the single ascending dose (SAD) group and 98% in the multiple ascending dose (MAD) group detected colon entry.
• The NaviCap devices were well tolerated by all participants in both SAD and MAD cohorts.
• The Phase 1 trial included 48 healthy participants, with 24 receiving single ascending doses and 24 receiving multiple ascending doses of BT-600 or placebo.

Sentiment

Score: 9

Explanation: The document presents very positive results from a Phase 1 clinical trial, with clear evidence of successful targeted drug delivery and reduced systemic exposure. The management's comments are also highly optimistic, indicating strong confidence in the technology and future prospects.

Positives

• The NaviCap platform successfully delivered tofacitinib directly to the colon, as intended.
• The trial showed a significant reduction in systemic drug exposure, potentially reducing side effects.
• The device was well-tolerated by all participants, indicating good safety.
• The results support advancing BT-600 into a Phase 1b clinical trial in patients with ulcerative colitis.
• The study demonstrated pan-colonic delivery, reaching common sites of disease.

Risks

• Cross-trial comparisons are not possible due to differences in trial design and patient populations.
• No head-to-head clinical trials have been conducted against conventional oral tofacitinib.
• The results are from a Phase 1 trial in healthy volunteers, and further trials in patients with ulcerative colitis are needed to confirm efficacy.

Future Outlook

Biora Therapeutics plans to advance BT-600 into a Phase 1b clinical trial in patients with ulcerative colitis, with a planned start in Q4 2024.

Management Comments

• Ariella Kelman, MD, Chief Medical Officer, stated that all study objectives were met and the NaviCap platform can deliver tofacitinib topically to the colon with lower peak systemic exposure.
• Adi Mohanty, Chief Executive Officer, expressed encouragement with the trial results, highlighting the potential to improve the efficacy of JAK inhibitors and other drug classes through anatomically targeted delivery.
• Adi Mohanty also mentioned that the BioJet platform is progressing well and is on track to meet previously stated goals.

Industry Context

The announcement is significant as it addresses the unmet need for targeted drug delivery in ulcerative colitis, where current treatments often have limited efficacy due to challenges in achieving sufficient drug activity at the site of disease. The NaviCap platform's ability to reduce systemic exposure could also mitigate side effects associated with conventional oral therapies.

Comparison to Industry Standards

• Conventional oral tofacitinib reaches maximal systemic levels in 30 minutes, while Biora's BT-600 reached maximal levels in 8-10 hours, indicating a significant difference in delivery.
• The maximal systemic drug exposure with BT-600 was three to four times lower than with conventional oral tofacitinib, suggesting a potential advantage in terms of reduced side effects.
• Other companies like Pfizer (Xeljanz) and AbbVie (Rinvoq) have oral JAK inhibitors for UC, but Biora's approach aims for targeted delivery to the colon, which could offer improved efficacy and reduced systemic exposure compared to these existing treatments.
• Companies like Takeda (Entyvio) and Janssen (Stelara) offer biologics for UC, which are administered via injection or infusion, while Biora's NaviCap platform offers a potential oral alternative.

Stakeholder Impact

• Shareholders are likely to react positively to the successful trial results and the potential for a new treatment option for ulcerative colitis.
• Patients with ulcerative colitis may benefit from a more effective and safer treatment option.
• Employees of Biora Therapeutics are likely to be motivated by the positive results and the progress of the company's technology.

Next Steps

• Biora Therapeutics will host a virtual event on July 17, 2024, to provide additional details on the Phase 1 trial results.
• The company plans to advance BT-600 into a Phase 1b clinical trial in patients with ulcerative colitis, with a planned start in Q4 2024.

Key Dates

Keywords

ulcerative colitis, BT-600, NaviCap, tofacitinib, targeted drug delivery, clinical trial, gastrointestinal, inflammatory bowel disease, oral delivery, pharmacokinetics